Treating metastatic disease with a modified herpesvirus

March 27, 2002

Using bacteria or viruses to control tumors is an old idea, and many such biotherapeutic agents have been designed and tested in cell and animal models. Safety concerns are paramount in this work, and most candidates with oncolytic properties have remained sidelined at the preclinical stage because, despite a general tropism towards cancer cells, they retain some ability to infect normal host cells or to cause systemic disease. Here, Nakamura and colleagues describe a second-generation derivative of the herpes simplex virus (HSV-1) that, they suggest, may be ready to clear this hurdle. A previously engineered form of HSV-1, deficient in the viral gene for the enzyme ribonucleotide reductase, replicated preferentially in liver tumor cells, which divide rapidly and possess sufficient pools of deoxynucleotides to support efficient viral replication. The newer recombinant virus, Myb34.5, has this same defect but also carries an engineered form of the g134.5 gene. The product of this gene allows the virus to circumvent a host cell defense mechanism that would otherwise shut down protein synthesis in infected cells. In Myb34.5, g134.5 is expressed under control of the Myb promoter, which is active in cycling cells, leaving the virus with extremely limited ability to proliferate in healthy host tissues. Nakamura et al. show that injection of Myb34.5 into mice carrying a high load of metastatic liver cells affords these animals considerable protection and significantly extends their survival. Even when provided at doses 10-fold higher than a rapidly fatal dose of wild-type HSV-1, Myb34.5 did not kill or paralyze treated mice. The authors caution, however, that neither mice nor other experimental animals provide fully adequate models for HSV-1 infection. Hence, viral toxicity in humans remains a possibility.

JCI Journals

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to